{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:37:56Z","timestamp":1784043476549,"version":"3.55.0"},"reference-count":53,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2013,11,8]],"date-time":"2013-11-08T00:00:00Z","timestamp":1383868800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:sec id=\"S1092852913000680_abs1\" sec-type=\"intro\"><jats:title>Introduction<\/jats:title><jats:p>All clinically effective antipsychotics are known to act on the dopaminergic system, and previous studies have demonstrated that repeated treatment with antipsychotics produced region-specific changes in dopamine receptor levels. Cariprazine is a dopamine D<jats:sub>3<\/jats:sub>and D<jats:sub>2<\/jats:sub>receptor partial agonist with preferential binding to D<jats:sub>3<\/jats:sub>receptors. We examined the effects of chronic cariprazine administration on dopamine receptor levels.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852913000680_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>Rats were administered either vehicle or cariprazine (0.06, 0.2, or 0.6 mg\/kg) for 28 days. Dopamine receptor levels were quantitated using autoradiographic assays on brain tissue sections from the medial prefrontal cortex (mPFC), nucleus accumbens (NAc), caudate putamen (CPu), hippocampus (HIPP), olfactory tubercle (OT), and islands of Calleja (ICj).<\/jats:p><\/jats:sec><jats:sec id=\"S1092852913000680_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Chronic treatment with cariprazine did not alter D<jats:sub>1<\/jats:sub>receptor levels in any brain region tested. Cariprazine increased D<jats:sub>2<\/jats:sub>receptor levels in mPFC (27%\u201343%), NAc (40%\u201345%), medial (41%\u201353%) and lateral (52%\u201363%) CPu, and HIPP (38%). Cariprazine dose-dependently upregulated D<jats:sub>3<\/jats:sub>receptor levels in ICj (32%\u201357%), OT (27%\u201367%), and NAc shell (31%\u201348%). Repeated cariprazine treatment increased D<jats:sub>4<\/jats:sub>receptor in NAc (53%\u201382%), medial (54%\u201398%) and lateral (58%\u201374%) CPu, and HIPP (38%\u201398%).<\/jats:p><\/jats:sec><jats:sec id=\"S1092852913000680_abs4\" sec-type=\"conclusion\"><jats:title>Conclusion<\/jats:title><jats:p>Similar to other antipsychotics, cariprazine upregulated D<jats:sub>2<\/jats:sub>and D<jats:sub>4<\/jats:sub>receptor levels in various brain regions. Cariprazine was unique among antipsychotics in increasing D<jats:sub>3<\/jats:sub>receptor levels, which may support its unique psychopharmacologic properties.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852913000680","type":"journal-article","created":{"date-parts":[[2013,11,8]],"date-time":"2013-11-08T14:14:51Z","timestamp":1383920091000},"page":"268-277","source":"Crossref","is-referenced-by-count":23,"title":["Long-term effects of cariprazine exposure on dopamine receptor subtypes"],"prefix":"10.1017","volume":"19","author":[{"given":"Yong Kee","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika","family":"Adham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Gyerty\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank I.","family":"Tarazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2013,11,8]]},"reference":[{"key":"S1092852913000680_ref46","doi-asserted-by":"publisher","DOI":"10.1080\/1029842021000045499"},{"key":"S1092852913000680_ref10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0022-3565(24)29589-6","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment","volume":"297","author":"Tarazi","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852913000680_ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)02024-7"},{"key":"S1092852913000680_ref23","unstructured":"Cutler AJ , Bose A , Durgam S , etal. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week extension study. Paper presented at: American Psychiatric Association (APA)\u2014165th Annual Meeting; May 5\u20139, 2012; Philadelphia, PA."},{"key":"S1092852913000680_ref22","unstructured":"Starace A , Bose A , Wang Q , etal. Cariprazine in the treatment of acute mania in bipolar disorder: a double-blind, placebo-controlled, Phase III trial. Paper presented at: American Psychiatric Association (APA)\u2014165th Annual Meeting; May 5\u20139, 2012; Philadelphia, PA."},{"key":"S1092852913000680_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(97)00112-7"},{"key":"S1092852913000680_ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-2096-z"},{"key":"S1092852913000680_ref33","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199711100-00001"},{"key":"S1092852913000680_ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-008-1098-7"},{"key":"S1092852913000680_ref17","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.160432"},{"key":"S1092852913000680_ref35","volume-title":"Statistical Principles in Experimental Design","author":"Winer","year":"1991"},{"key":"S1092852913000680_ref8","first-page":"1","volume-title":"Schizophrenia and Mood Disorders","author":"Waddington","year":"2000"},{"key":"S1092852913000680_ref21","unstructured":"Knesevich MA , Papadakis K , Bose A , etal. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a Phase II trial. Paper presented at: American Psychiatric Association (APA)\u2014162nd Annual Meeting; May 16\u201321, 2009; San Francisco, CA."},{"key":"S1092852913000680_ref11","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.052597"},{"key":"S1092852913000680_ref41","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(89)90074-X"},{"key":"S1092852913000680_ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0006-7"},{"key":"S1092852913000680_ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1016-3"},{"key":"S1092852913000680_ref47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2012.01910.x"},{"key":"S1092852913000680_ref31","volume-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1986"},{"key":"S1092852913000680_ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2003.10.004"},{"key":"S1092852913000680_ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2010.02.003"},{"key":"S1092852913000680_ref45","doi-asserted-by":"crossref","unstructured":"Kiss B , Horti F , Bobok A . Cariprazine, a D3\/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Paper presented at: 3rd Biennial Schizophrenia International Research Society Congress; April 14\u201318, 2012; Florence, Italy.","DOI":"10.1016\/S0920-9964(12)70588-1"},{"key":"S1092852913000680_ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-010-1005-8"},{"key":"S1092852913000680_ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.02.005"},{"key":"S1092852913000680_ref14","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108095704"},{"key":"S1092852913000680_ref27","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-25758-2_7"},{"key":"S1092852913000680_ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(97)00046-8"},{"key":"S1092852913000680_ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0004-9"},{"key":"S1092852913000680_ref16","doi-asserted-by":"publisher","DOI":"10.1124\/pr.107.00107"},{"key":"S1092852913000680_ref38","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246070"},{"key":"S1092852913000680_ref2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.002642"},{"key":"S1092852913000680_ref39","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2847-07.2007"},{"key":"S1092852913000680_ref3","doi-asserted-by":"publisher","DOI":"10.3109\/10673229609017200"},{"key":"S1092852913000680_ref48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2010.00831.x"},{"key":"S1092852913000680_ref1","first-page":"461","volume-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics","author":"Baldessarini","year":"2005"},{"key":"S1092852913000680_ref26","first-page":"128","article-title":"In vitro metabolism of RGH-188","volume":"40","author":"Kirschner","year":"2008","journal-title":"Drug Metab Rev"},{"key":"S1092852913000680_ref4","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2011.575061"},{"key":"S1092852913000680_ref40","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(92)90242-R"},{"key":"S1092852913000680_ref34","volume-title":"Econometric analysis","author":"Greene","year":"2000"},{"key":"S1092852913000680_ref18","unstructured":"Bose A , Li D , Migliore R , etal. The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. Paper presented at: New Clinical Drug Evaluation Unit (NCDEU)\u201450th Annual Meeting; June 14\u201317, 2010; Boca Raton, FL."},{"key":"S1092852913000680_ref30","doi-asserted-by":"publisher","DOI":"10.2165\/11314280-000000000-00000"},{"key":"S1092852913000680_ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050147"},{"key":"S1092852913000680_ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(96)00631-8"},{"key":"S1092852913000680_ref5","doi-asserted-by":"publisher","DOI":"10.2174\/138161210790361461"},{"key":"S1092852913000680_ref7","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2011.556112"},{"key":"S1092852913000680_ref32","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-3565(24)36475-4","article-title":"Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs","volume":"280","author":"Florijn","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852913000680_ref12","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20618"},{"key":"S1092852913000680_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(12)70588-1"},{"key":"S1092852913000680_ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-008-0311-x"},{"key":"S1092852913000680_ref43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300940"},{"key":"S1092852913000680_ref50","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.134536"},{"key":"S1092852913000680_ref53","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830180085011"},{"key":"S1092852913000680_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2011.07.002"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852913000680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T19:56:42Z","timestamp":1746043002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852913000680\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,8]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1092852913000680"],"URL":"https:\/\/doi.org\/10.1017\/s1092852913000680","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,8]]}}}